Incannex Healthcare (IXHL) Expected to Release Earnings on Friday

Incannex Healthcare (NASDAQ:IXHL) is anticipated to issue its Q1 2027 results on Friday, November 13th. Analysts expect the company to post earnings of ($0.66) per share and revenue of $10.00 million for the quarter. Investors may visit the company’s upcoming Q1 2027 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.

Incannex Healthcare (NASDAQ:IXHL) last announced its quarterly earnings data on Saturday, September 26th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.27). On average, analysts expect Incannex Healthcare to post ($2.63) EPS for the current fiscal year and ($2.77) EPS for the next fiscal year.

Incannex Healthcare Stock Performance

Shares of NASDAQ IXHL opened at $1.98 on Thursday. Incannex Healthcare has a 1 year low of $1.96 and a 1 year high of $14.91. The firm’s 50 day moving average price is $2.97 and its 200 day moving average price is $3.92. The firm has a market cap of $24.85 million, a P/E ratio of -1.17 and a beta of 7.00.

Analyst Ratings Changes

Several research analysts have weighed in on IXHL shares. Wall Street Zen downgraded Incannex Healthcare from a “hold” rating to a “sell” rating in a report on Saturday, October 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Incannex Healthcare in a report on Thursday, October 15th. Finally, Zacks Research cut Incannex Healthcare from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 6th. One equities research analyst has rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $18.00.

Incannex Healthcare Company Profile

Incannex Healthcare Limited (NASDAQ: IXHL) is an Australia-based clinical-stage pharmaceutical company developing cannabinoid- and psychedelic-assisted therapies for conditions with significant unmet medical needs. The company’s research programs are focused on areas including sleep disorders, pain, inflammation, mental health and traumatic brain injury. Incannex’s lead programs have included IHL-42X, an investigational combination therapy being developed for obstructive sleep apnea, and IHL-675A, a cannabinoid-based therapy studied for inflammatory conditions.